Cryoport（CYRX）株式概要
Cryoport, Inc.は、世界中のバイオ医薬品/製薬、動物医療、生殖医療市場において、温度制御サプライチェーンソリューションを提供しています。 詳細
CYRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cryoport, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$15.70 |
| 52週高値 | US$16.73 |
| 52週安値 | US$6.69 |
| ベータ | 1.89 |
| 1ヶ月の変化 | 0.064% |
| 3ヶ月変化 | 84.49% |
| 1年変化 | 114.77% |
| 3年間の変化 | -9.67% |
| 5年間の変化 | -74.29% |
| IPOからの変化 | -85.86% |
最新ニュース
ナラティブの更新 • Jun 26
CYRX: Bioservices Demand And Service Mix Will Drive Future Upside
The analyst price target for Cryoport has been raised from $16.00 to about $19.93. Analysts cite stronger expected revenue growth, slightly higher margin assumptions, and a modestly lower future P/E multiple as key factors behind their updated view.
ナラティブの更新 • Jun 12
CYRX: Differentiated Bioservices And Regulatory Support Will Shape Balanced Forward Outlook
Cryoport's analyst price target has moved up by $2 to $15.61, with analysts pointing to stronger appreciation for its differentiated bioservices offering, higher perceived revenue visibility and margin potential, and ongoing regulatory and funding support for growth as key drivers of their updated views. Analyst Commentary Recent research updates have centered on Cryoport's bioservices operations, with several firms revisiting their valuation frameworks after site visits and a review of end market conditions.Recent updates
ナラティブの更新 • Jun 26
CYRX: Bioservices Demand And Service Mix Will Drive Future Upside
The analyst price target for Cryoport has been raised from $16.00 to about $19.93. Analysts cite stronger expected revenue growth, slightly higher margin assumptions, and a modestly lower future P/E multiple as key factors behind their updated view.ナラティブの更新 • Jun 12
CYRX: Differentiated Bioservices And Regulatory Support Will Shape Balanced Forward Outlook
Cryoport's analyst price target has moved up by $2 to $15.61, with analysts pointing to stronger appreciation for its differentiated bioservices offering, higher perceived revenue visibility and margin potential, and ongoing regulatory and funding support for growth as key drivers of their updated views. Analyst Commentary Recent research updates have centered on Cryoport's bioservices operations, with several firms revisiting their valuation frameworks after site visits and a review of end market conditions.
ナラティブの更新 • May 29
CYRX: Elevated Expectations For Service Group Margins Will Challenge Execution
Analysts have lifted their price targets on Cryoport, prompting an updated fair value estimate from $9.51 to $11.00, citing stronger revenue visibility, improved margin expectations through 2028, and a broad base of commercial and clinical customers as key supports for the stock. Analyst Commentary Recent Street research has leaned constructive on Cryoport, with several firms lifting price targets and highlighting the company’s revenue visibility, margin profile through 2028, and breadth of commercial and clinical relationships.ナラティブの更新 • May 03
CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside
Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.ナラティブの更新 • Apr 19
CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook
Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.ナラティブの更新 • Apr 03
CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns
Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.ナラティブの更新 • Mar 20
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.ナラティブの更新 • Mar 04
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).ナラティブの更新 • Feb 18
CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects
Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).ナラティブの更新 • Feb 04
CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects
Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).ナラティブの更新 • Jan 21
CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.ナラティブの更新 • Jan 06
CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects
Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.ナラティブの更新 • Dec 20
CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects
Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.ナラティブの更新 • Dec 06
CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside
Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.ナラティブの更新 • Nov 22
CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery
The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.ナラティブの更新 • Nov 06
CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound
Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.ナラティブの更新 • Aug 07
Cold Chain Expansion Will Support Cell And Gene Therapies
Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.分析記事 • Jul 22
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 1.4x Cryoport, Inc. ( NASDAQ:CYRX ) may be sending very bullish signals at...分析記事 • May 30
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
Key Insights Cryoport will host its Annual General Meeting on 6th of June Salary of US$921.2k is part of CEO Jerry...分析記事 • Apr 09
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
新しいナラティブ • Mar 30
New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply
Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.分析記事 • Mar 06
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders of Cryoport, Inc. ( NASDAQ:CYRX ) will be pleased this week, given that the stock price is up 17% to...分析記事 • Feb 22
Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Cryoport, Inc. ( NASDAQ:CYRX ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Dec 03
Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Cryoport, Inc. ( NASDAQ:CYRX ) is a stock worth...分析記事 • Nov 06
Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Aug 09
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Those holding Cryoport, Inc. ( NASDAQ:CYRX ) shares would be relieved that the share price has rebounded 36% in the...株主還元
| CYRX | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 6.4% | 9.8% | 0.3% |
| 1Y | 114.8% | 17.2% | 19.9% |
業界別リターン: CYRX過去 1 年間で17.2 % の収益を上げたUS Life Sciences業界を上回りました。
リターン対市場: CYRX過去 1 年間で19.9 % の収益を上げたUS市場を上回りました。
価格変動
| CYRX volatility | |
|---|---|
| CYRX Average Weekly Movement | 8.3% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: CYRX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CYRXの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1999 | 688 | Jerry Shelton | www.cryoportinc.com |
Cryoport, Inc.は、世界中のバイオ医薬品／製薬、動物医療、生殖医療市場において、温度管理されたサプライチェーン・ソリューションを提供している。ライフサイエンスサービス部門は、ライフサイエンス業界において、温度管理されたロジスティクス、バイオストレージ、バイオサービス、凍結保存サービスを提供している。ライフサイエンス製品部門は、極低温冷凍庫、極低温デュワー、関連付属品を製造し、直販または流通ネットワークを通じてライフサイエンス業界に販売している。同社の製品には、Cryoport Express Shippers、Cryoport Elite、Cryoport Express Cryogenic HV3 Shipping System、Smartpak Condition Monitoring System、IoTベースのモニタリングソリューションであるTec4Med、Cryoportアクセサリなどがある。また、Cryoport Systems BioservicesなどのCryoport BioStorage/Bioservicesも提供しており、これには温度管理された保管、キッティング、ラベリング、フルフィルメント、サンプル管理、医薬品返却、Qualified Person医薬品リリースなどが含まれる。さらに、アフェレシス/ロイカフェレシス採取、クライオシャトル輸送、クライオプロセス最適化、凍結保存サービスからなるIntegriCellサービス、Cryoportコンサルティングサービス、自立型クライオフリーザーであるMVE Fusionクライオジェニックシステム、クライオジェニックフリーザーシステムであるMVE Varioクライオジェニックシステムを提供している。さらに、生物試料の凍結保存とメンテナンス、試料のアーカイブ、モニタリング、追跡、受領、配送、凍結生物試料の輸送、生物試料の入出庫管理、短期ロジスティクスとエンジニアリングのコンサルティングサービスも提供している。同社は1999年に設立され、テネシー州ブレントウッドを拠点としている。
Cryoport, Inc. 基礎のまとめ
| CYRX 基礎統計学 | |
|---|---|
| 時価総額 | US$820.55m |
| 収益（TTM） | -US$44.66m |
| 売上高(TTM) | US$182.94m |
4.3x
P/Sレシオ-17.7x
PER（株価収益率CYRX は割高か？
公正価値と評価分析を参照収益と収入
| CYRX 損益計算書（TTM） | |
|---|---|
| 収益 | US$182.94m |
| 売上原価 | US$96.61m |
| 売上総利益 | US$86.33m |
| その他の費用 | US$130.99m |
| 収益 | -US$44.66m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.89 |
| グロス・マージン | 47.19% |
| 純利益率 | -24.41% |
| 有利子負債／自己資本比率 | 37.7% |
CYRX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/30 01:07 |
| 終値 | 2026/06/30 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cryoport, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Yuan Zhi | B. Riley Securities, Inc. |